New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026
Nov 6, 2026 11:25 AM